Argenx

Argenx has developed an innovative approach to antibody engineering. The biotechnology company medication development pipeline includes antibody treatments for cancer as well as inflammatory and autoimmune illnesses.

Argenx released positive phase III data for their lead drug candidate efgartigimod in the year 2020. These results demonstrated that the medicine had alleviated the motor symptoms of patients who were living with the autoimmune condition myasthenia gravis.

Efgartigimod's authorisation application is now being reviewed by regulatory authorities in Europe, the United States of America, and Japan; the results of this evaluation are anticipated to be available in the middle of 2022. Argenx is traded on both the Euronext and the Nasdaq in the United States.

Founded: 2008
Headquarters: Breda, Netherlands
Website: https://www.argenx.com/